Long Position on VNDA @ $21.90 on 8/9/2018 (Momentum)

Vanda Pharmaceuticals Inc. (VNDA) is a biopharmaceutical company.

The firm focuses on the development and commercialization of products for the treatment of central nervous system disorders.

The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Canada, Europe, Israel, and Mexico. 

Shares have formed a bullish "cup and handle" and are on the cusp of a breakout. Higher share prices are expected for this stock.

Entry Point: $21.90

Stop Loss: $20.80

Trading Range: $11.90 - $23.35

Target Price: $24.09

Updates

11/8/2018 11:18:47 AM

VNDA closed at $24.15

Position closed on 11/8/2018 at price of $24.15 with a 10.27% gain in 91 days.

Back to Portfolio